What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?
about
Mitochondria-associated ER membranes and Alzheimer diseaseAnalysis of beta-amyloid (Abeta) deposition in the temporal lobe in Alzheimer's disease using Fourier (spectral) analysis.Size frequency distribution of the beta-amyloid (abeta) deposits in dementia with Lewy bodies with associated Alzheimer's disease pathologyFrom model system to clinical medicine: pathophysiologic links of common proteinopathies.A morphometric study of the spatial patterns of TDP-43 immunoreactive neuronal inclusions in frontotemporal lobar degeneration (FTLD) with progranulin (GRN) mutation.A quantitative study of the neuropathology of 32 sporadic and familial cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP).Supramolecular non-amyloid intermediates in the early stages of α-synuclein aggregation.Different molecular pathologies result in similar spatial patterns of cellular inclusions in neurodegenerative disease: a comparative study of eight disordersDry age-related macular degeneration: mechanisms, therapeutic targets, and imaging.Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy.APP physiological and pathophysiological functions: insights from animal models.Role of proteomics in understanding prion infection.Oculo-visual changes and clinical considerations affecting older patients with dementia.Comparative quantitative study of 'signature' pathological lesions in the hippocampus and adjacent gyri of 12 neurodegenerative disorders.Distribution of granulocyte-monocyte colony-stimulating factor and its receptor α-subunit in the adult human brain with specific reference to Alzheimer's disease.Four-repeat tauopathy clinically presenting as posterior cortical atrophy: atypical corticobasal degeneration?
P2860
Q26745495-6019B8C9-9D79-426C-977E-59833FC974A7Q30476109-4443AE3F-9CA0-408E-A503-17461B5473CDQ33604063-F6B59450-A9F8-4694-AD86-E25A871CDE09Q34318017-594F711F-D901-4F1F-8887-E61FF8BF1C35Q34473037-0EA8865C-A191-4CB7-B887-3B01654308F5Q35501862-6865F113-D90F-4649-A0B3-D9A340DF9257Q35810050-DBD5307F-A9E9-4520-8A51-CD0E7B9D3E86Q37392690-9317CC0D-6C64-49B7-8374-8B37A67AB8F3Q37395303-8390ED97-1CD1-4534-B678-B11AE95897F2Q37461525-458DCFBD-C502-43E8-AD4D-F269D9E6BE24Q37902514-FA262A80-1774-4652-B59B-877EBC0EF332Q38068928-76EBB284-843F-46C5-9A09-D6F58B8F6C2FQ38533327-BCFC8C01-E670-43F8-BFB6-72F7CD83CA2CQ40992216-036C7D22-5C15-4393-9D65-9C6CF20444DEQ44913965-27D50C54-1CB6-455E-BC82-8368F45F5844Q48155467-BFD40753-1F93-4D55-929F-96DB41B09AAB
P2860
What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
What determines the molecular ...... in neurodegenerative disease?
@en
What determines the molecular ...... in neurodegenerative disease?
@nl
type
label
What determines the molecular ...... in neurodegenerative disease?
@en
What determines the molecular ...... in neurodegenerative disease?
@nl
prefLabel
What determines the molecular ...... in neurodegenerative disease?
@en
What determines the molecular ...... in neurodegenerative disease?
@nl
P2093
P2860
P1433
P1476
What determines the molecular ...... in neurodegenerative disease?
@en
P2093
Nigel J Cairns
Peter L Lantos
Richard A Armstrong
P2860
P304
P356
10.1111/J.1440-1789.2008.00916.X
P577
2008-04-23T00:00:00Z